IBA Collaborates with AIG for Innovative Cancer Treatment
In a remarkable move to enhance cancer treatment options, IBA (Ion Beam Applications S.A.), a leader in particle accelerator technology, has officially partnered with the Asian Institute of Gastroenterology (AIG) to deliver an advanced proton therapy solution. This collaboration marks a significant milestone for both organizations and aims to bolster cancer care in the region.
ProteusONE System: A Game Changer in Proton Therapy
The heart of this partnership is the Proteus®ONE system, an innovative compact proton therapy system designed to provide precise and effective treatment options for cancer patients. This system, which is slated for placement at the Oncology Centre within AIG Hospitals' Gachibowli campus, exemplifies cutting-edge technology, making it the first of its kind in South Asia. As IBA continues to lead the way in proton therapy advancements, the Proteus®ONE system promises to meet the growing demand for advanced cancer treatments.
Details of the Agreement
This binding agreement ensures that AIG receives not only the Proteus®ONE system but also a comprehensive Quality Assurance package from IBA Dosimetry. The importance of this system cannot be overstated, as it is recognized for its efficiency and capability to be upgraded with the latest technology over time. Furthermore, the system is expected to include DynamicARC® beam delivery capabilities, pending regulatory approval.
Executive Insights
Olivier Legrain, the Chief Executive Officer of IBA, stated, "This new contract demonstrates IBA’s strong position to meet the growing demand for proton therapy technology. We are excited to facilitate access to this advanced treatment for cancer patients in the region." His sentiments are echoed by Dr. D Nageshwar Reddy, Chairman of AIG Hospitals, who emphasized the hospital's dedication to transforming patient care in cancer treatment.
Significance of Proton Therapy in Cancer Treatment
The introduction of the Proteus®ONE system is a critical step in addressing cancer treatment needs in India. Proton therapy is known for its precision, allowing for targeted treatment while minimizing damage to surrounding healthy tissues—a crucial factor in enhancing patient recovery outcomes. AIG Hospitals, recognized among the top centers for gastroenterology, is committed to integrating such advanced technologies to better serve patients.
Future Prospects
As the third proton therapy center planned in the country and the second in the private sector, AIG anticipates starting patient treatments by 2028. The investment in this technology reflects a broader commitment across the healthcare industry to embrace innovative solutions that improve cancer treatment accessibility and effectiveness.
About IBA and AIG
IBA (Ion Beam Applications S.A.) has established itself as the global leader in particle accelerator technology, providing essential equipment and services in proton therapy. Additionally, IBA plays a vital role in areas such as industrial sterilization, radiopharmaceuticals, and dosimetry. With a workforce of approximately 2,000 employees worldwide, IBA continues to uphold the highest standards as a certified B Corporation.
AIG Hospitals, part of the Asian Institute of Gastroenterology, has emerged as a top facility dedicated to gastroenterology. Having started operations in 2018, it spans over 1.4 million square feet and currently features 825 beds, with plans to expand significantly. The commitment to research and academic excellence is evident, having published close to 1,500 papers in peer-reviewed journals. With these advancements, AIG Hospitals aims to set high standards in patient care.
Frequently Asked Questions
What is the Proteus®ONE system?
The Proteus®ONE system is a compact proton therapy system designed to provide precise cancer treatment while minimizing damage to healthy tissues.
Where will the new Proteus®ONE system be located?
The new system will be located at the Oncology Centre within AIG Hospitals' Gachibowli campus.
When is AIG expected to start treating patients?
AIG Hospitals aims to begin patient treatments with the new system by early 2028.
What are the benefits of proton therapy?
Proton therapy offers targeted treatment that reduces harm to surrounding healthy tissues, leading to better recovery options for patients.
Who is involved in this agreement?
This partnership involves IBA, a leader in particle accelerator technology, and AIG Hospitals, a prominent player in the field of gastroenterology and advanced cancer care.
